Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer: A phase II trial conducted by the Groupe Français de Pneumo-Cancérologie (GFPC)

Lung Cancer

Volumn 47, Issue 3, 2005, Pages 395-404

  Vergnenegre A ^a   Daniel, C ^b   Lena H ^c   Fournel, P ^d   Kleisbauer, J P ^e   Le Caer, H ^f   Letreut, J ^g   Paillotin, D ^h   Perol M ⁱ   Bouchaert, E ^j   Preux, P M ^a   Robinet, G ^b  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f CH de Draguignan   (France)

^g CH de Aix en Provence   (France)

^h ROUEN UNIVERSITY HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j CH d'Elbeuf   (France)

more..

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Phase II; Radiotherapy

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CISPLATIN; DEXAMETHASONE; DOCETAXEL; GROWTH FACTOR; NAVELBINE; PROTON PUMP INHIBITOR; STEROID;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DERMATITIS; DIARRHEA; DRUG HYPERSENSITIVITY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEARING DISORDER; HEMOPTYSIS; HUMAN; INFECTION; INOPERABLE CANCER; KIDNEY FAILURE; LUNG ASPERGILLOSIS; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL;

EID: 13844255948     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.08.010     Document Type: Conference Paper

References (32)

1. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on 16 May 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
2. E. Bardet, D. Moro-Sibilot, T. Le Chevalier, G. Massard, J.Y. Douillard, and S. Theobald Standards, options and recommendations for the management of locally advanced non-small-cell lung carcinoma Bull Cancer 88 2001 369 387
3. S. Atagi, M. Kawahara, S. Hosoe, M. Ogawara, T. Kawaguchi, and K. Okishio A phase II study of continuous concurrent thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer Lung Cancer 36 2002 105 111
4. K.S. Albain, J.J. Crowley, A.T. Turrisi III, D.R. Gandara, W.B. Farrar, and J.I. Clark Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group. Phase II study, SWOG 9019 J Clin Oncol 20 2002 3454 3460
5. K. Furuse, M. Fukuoka, M. Kawahara, H. Nishikawa, Y. Takada, and S. Kudoh Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
6. W.J. Curran, C.B. Scott, R. Langer, R. Komaki, J.S. Lee, and S. Hauser Long-term benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG Proc Am Soc Clin Oncol (Chicago) 22 2003 2499 [abstract]
7. P. Fournel, M. Perol, G. Robinet, P. Thomas, P.J. Souquet, and H. Lena A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non-small-cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study) Proc Am Soc Clin Oncol (St Fransisco) 20 2001 246 [abstract]
8. O. Caffo Radiosensitization with chemotherapeutic agents Lung Cancer 34 Suppl 4 2001 S81 S90
9. E. Vokes, J.E. Herndon, J. Crawford, K. Leopold, M. Perry, and A. Miller Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukenia group B study 9431 J Clin Oncol. 20 2002 4191 4198
10. C.P. Belani Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small-cell lung cancer Semin Oncol 26 1999 44 54
11. F.A. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, and M. O'Rourke Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
12. D. Gandara, K. Chansky, K.S. Albain, B. Leigh, L.E. Gaspar, and P. Lara Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504 J Clin Oncol 21 2003 2004 2010
13. J. Cortes, and R. Pazdur Docetaxel J Clin Oncol 13 1995 2643 2655
14. H. Choy, F. Rodriguez, and S. Koester Synergistic effects of taxol/taxotere on radiation sensitivity on human tumor cell lines Int J Radiat Oncol Biol Phys 24 1993 274 275
15. A.M. Mauer, G.A. Masters, D.J. Haraf, P.C. Hoffman, S.M. Watson, and H.M. Golomb Phase I study of docetaxel with concomitant thoracic radiation therapy J Clin Oncol 16 1998 159 164
16. M.I. Koukourakis, C. Kourousis, M. Kamilaki, S. Koukouraki, A. Giatromanolaki, and S. Kakolyris Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer. A phase I/II dose escalation trial Eur J Cancer 34 1998 838 844
17. M. Teng, H. Choy, and R. DeVore Phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable NSCLC: a Vanderbilt Cancer Center Affiliate Network trial Proc Am Soc Clin Oncol (Los Angeles) 17 1998 1938 [abstract]
18. S. Aamdal, M. Hallen, and D. Tonelli Docetaxel (Taxotere) combined with radiation in locally advanced NSCLC: A phase I/II study Proc Am Soc Clin Oncol (Los Angeles) 17 1998 1830 [abstract]
19. M.I. Koukourakis, N. Bahlitzanakis, M. Froudarakis, A. Giatromanolaki, V. Georgoulias, and S. Koumiotaki Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma Br J Cancer 80 1999 1792 1796
20. J. Sistermanns, and H. Hoffmanns Phase II study of docetaxel with simultaneous radiochemotherapy in patients with locally advanced non-resectable non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol (Atlanta) 18 1999 2014 [abstract]
21. R. Mudad, M. Ramsey, K. Kovitz, T.J. Curiel, R. Hartz, and L.L. Nedzi Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small-cell lung cancer: a dose finding study Lung Cancer 39 2003 173 177
22. A.J. Wozniak, J.J. Crowley, S. Balcerzak, G. Weiss, C. Spiridonidis, and L. Baker Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study J Clin Oncol 16 1998 2459 2465
23. International Commission on Radiation units and measurements and (ICRU). Prescribing, recording ant reporting photon beam therapy. Washington, DC: ICRU; 1993.
24. M.V. Graham, J.A. Purdy, B. Emami, W. Harms, W. Bosch, and M.A. Lockett Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small-cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys 45 1999 323 329
25. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
26. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
27. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
28. J.E. Herndon II A design alternative for two-stage, phase II, multicenter cancer clinical trials Control Clin Trials 19 1998 440 450
29. E.E. Vokes, A.M. Mauer, P.C. Hoffman, and D.J. Haraf Combined modality therapy in non-small-cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy Semin Oncol 25 1998 28 32
30. Manegold C, Ramlau R, Scagliotti G, Buchholz E, Szczesna A, Cardenal F, et al. A phase II randomized study of thoracic radiotherapy with or without weekly docetaxel following docetaxel-cisplatin induction chemotherapy in unresectable stages IIIA-IIIB non-small-cell lung cancer. Lung Cancer 2003:243.
31. H. Onishi, K. Kuriyama, M. Yamaguchi, T. Komiyama, S. Tanaka, and T. Araki Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small-cell lung cancer: a good local response but no good survival due to radiation pneumonitis Lung Cancer 40 2003 79 84
32. M.I. Koukourakis, K. Romanidis, M. Froudarakis, G. Kyrgias, G.V. Koukourakis, and G. Retalis Concurrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small-cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection Br J Cancer 87 2002 385 392